Heart failure in the elderly

Current Opinion in Cardiology

Volumn 28, Issue 2, 2013, Pages 234-241

  Chan, Michael ^a   Tsuyuki, Ross ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

elderly; geriatric; heart failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; BISOPROLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; METOPROLOL; NEBIVOLOL; SPIRONOLACTONE;

CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR SYSTEM EXAMINATION; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITIVE DEFECT; COMORBIDITY; EXERCISE; HEART FAILURE; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC RESYNCHRONIZATION THERAPY; DEFIBRILLATORS, IMPLANTABLE; EXERCISE; HEART FAILURE; HUMANS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84873466751     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32835dd0e9     Document Type: Review

References (65)

1. World Health Organization (WHO). Definition of an older or elderly person. http://www.who.int.login.ezproxy.library.ualberta.ca/healthinfo/survey/ ageingdefnolder/en/print.html. [Accessed 26 August 2012]
2. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic HF 2008: The task force for the diagnosis and treatment of acute and chronic HF 2008 of the European Society of Cardiology. Developed in collaboration with the HF Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 10:933-989.
3. Tsuyuki RT, Shibata MC, Nilsson C, Hervas-Malo M. Contemporary burden of illness of congestive HF in Canada. Can J Cardiol 2003; 19:436-438.
4. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics Y 2010 update: A report from the American Heart Association. Circulation 2010; 121:e46-e215.
5. Cleland JG, McDonagh T, Rigby AS, et al. The national HF audit for England and Wales 2008-2009. Heart 2011; 97:876-886.
6. Shah RU, Tsai V, Klein L, Heidenreich PA. Characteristics and outcomes of very elderly patients after first hospitalization for HF. Circ Heart Fail 2011; 4:301-307.
7. Maisel A, Mueller C, Adams K Jr, et al. State of the art: Using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10:824-839.
8. Oudejans I, Mosterd A, Bloemen JA, et al. Clinical evaluation of geriatric outpatients with suspected HF: value of symptoms, signs, and additional tests. Eur J Heart Fail 2011; 13:518-527.
9. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle HF Model; prediction of survival in HF. Circulation 2006; 113:1423-1433.
10. Komajda M, Hanon O, Hochadel M, et al. Contemporary management of octogenarians hospitalized for HF in Europe: Euro HF Survey II. Eur Heart J 2009; 30:478-486.
11. Komajda M, Carson PE, Hetzel S, et al. Factors associated with outcome in HF with preserved ejection fraction: findings from the Irbesartan in HF with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail 2011; 4:27-35.
12. Manzano L, Babalis D, Roughton M, et al. Predictors of clinical outcomes in elderly patients with HF. Eur J Heart Fail 2011; 13:528-536.
13. Hamaguchi S, Kinugawa S, Goto D, et al. Predictors of long-term adverse outcomes in elderly patients over 80 years hospitalized with HF. A report from the Japanese Cardiac Registry of HF in Cardiology (JCARE-CARD). Circ J 2011; 75:2403-2410.
14. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive HF. JAMA 1996; 275:1557-1566.
15. Dunlay SM, Weston SA, Jacobsen SJ, Roger VL. Risk factors for HF: A population-based caseYcontrol study. Am J Med 2009; 122:1023-1028.
16. Rich MW. Office management of HF in the elderly. Am J Med 2005; 118:342-348.
17. Butler J, Kalogeropoulos AP, Gerogiopoulou VV, et al. Systolic blood pressure and incident HF in the elderly. The Cardiovascular Health Study and the Health, Ageing and Body Composition Study. Heart 2011; 97:1304-1311.
18. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of HF with preserved ejection fraction. N Engl J Med 2006; 355:251-259.
19. Oudejans I, Mosterd A, Zuithoff NP, Hoes AW. Comorbidity drives mortality in newly diagnosed HF: A study among geriatric outpatients. J Card Fail 2012; 18:47-52.
20. Mascarenhas J, Lourenço P, Lopes R, et al. Chronic obstructive pulmonary disease in HF. Prevalence, therapeutic, and prognostic implications. Am Heart J 2008; 155:521-525.
21. Krumholz HM, Chen YT, Vaccarino V, et al. Correlates and impact on outcomes of worsening renal function in patients > or 65 years with HF. Am J Cardiol 2000; 85:1110-1113.
22. Maeder MT, Rickli H, Pfisterer ME, et al. Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic HF on intensive medical therapy. Am Heart J 2012; 163:407-414; 414.e1.
23. Heckman GA, Patterson CJ, Demers C, et al. HF and cognitive impairment: challenges and opportunities. Clin Interv Aging 2007; 2:209-218.
24. Heiat A, Gross CP, Krumholz HM. Representations of the elderly, women, and minorities in HF clinical trials. Arch Intern Med 2002; 162:1682-1688.
25. Mortality risk and patterns of practice in 4606 acute care patients with congestive HF. The relative importance of age, sex, and medical therapy. Clinical Quality Improvement Network Investigators. Arch Intern Med 1996; 156:1669-1673.
26. Shibata MC, Soneff CM, Tsuyuki RT. Utilization of evidence-based therapies for HF in the institutionalized elderly. Eur J Heart Fail 2005; 7:1122-1125.
27. Forman DE, Cannon CP, Hernandez AF, et al. Influence of age on the management of HF: findings from Get With the Guidelines-HF (GWTG-HF). Am Heart J 2009; 157:1010-1017.
28. Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with HF or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355:1575-1581.
29. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic HF (PEP-CHF) study. Eur Heart J 2006; 27:2338-2345.
30. Yusuf S, Pfeffer MA, Swedberg K, et al. Effect of candesartan in patients with chronic HF and preserved left-ventricular ejection fraction; the CHARMPreserved trial. Lancet 2003; 362:777-781.
31. Massie B, Carson PE, Mc Murray JJ, et al. Irbesartan in patients with HF and preserved ejection fraction. N Engl J Med 2008; 359:2456-2467.
32. Richardson DM, Bain KT, Diamond JJ, et al. Effectiveness of guidelinerecommended cardiac drugs for reducing mortality in the elderly medicare HF population: A retrospective, survey-weighted, cohort analysis. Drugs Aging 2010; 27:845-854.
33. Deedwania PC, Gottlieb S, Ghali JK, et al. Efficacy, safety and tolerability of b-adrenergic blockade with metoprolol CR/XL in elderly patients with HF. Eur Heart J 2004; 25:1300-1309.
34. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic HF. N Engl J Med 2001; 344:1651-1658.
35. Coats AJ. b-Adrenoceptor antagonists in elderly patients with chronic HF: Therapeutic potential of third-generation agents. Drugs Aging 2006; 23: 93-99.
36. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with HF (SENIORS). Eur Heart J 2005; 26:215-225.
37. Dobre D, van Veldhuisen DJ, Mordenti G, et al. Tolerability and dose-related effects of nebivolol in elderly patients with HF: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with HF (SENIORS) trial. Am Heart J 2007; 154:109-115.
38. Baxter AJ, Spensley A, Hildreth A, et al. Beta blockers in older persons with HF; tolerability and impact on quality of life. Heart 2002; 88:611-614.
39. Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11 942 elderly patients with HF. Am J Med 2002; 113:650-656.
40. Ambrosio G, Flather MD, Bohm M, et al. b-Blockade with nebivolol for prevention of acute ischaemic events in elderly patients with HF. Heart 2011; 97:209-214.
41. Hernandez AF, Hammill BG, O'Connor CM, et al. Clinical effectiveness of beta-blockers in HF: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with HF) Registry. J Am Coll Cardiol 2009; 53:184-192.
42. Düngen HD, Apostolovic S, Inkrot S, et al. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with HF: The CIBIS-ELD trial. Eur J Heart Fail 2011; 13:670-680.
43. Pitt B, Zannad F, Remme WJ, et al.; for the RALES Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe HF. N Engl J Med 1999; 341:709-717.
44. Pitt B, Remme W, Zannad F, et al.; for the EPHESUS Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
45. Zannad F, McMurray JJV, Krum H, et al.; for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic HF and mild symptoms. N Engl J Med 2011; 364:11-21.
46. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with HF. N Engl J Med 2004; 351:2049-2057.
47. Taylor AL, Sabolinski ML, Tam SW, et al. Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African-American HF trial. J Card Fail 2012; 18:600-606.
48. Gaggin HK, Mohammed AA, Bhardwaj A, et al. HF outcomes and benefits of NT-proBNP-guided management in the elderly: Results from the prospective, randomized ProBNP outpatient tailored chronic HF therapy (PROTECT) study. J Card Fail 2012; 18:626-634.
49. Pfisterer M, Buser P, Rickli H, et al. BNP-guided vs symptom-guided HF therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients with congestive HF (TIME-CHF) randomized trial. JAMA 2009; 301:383-392.
50. Stevenson WG, Hernandez AF, Carson PE, et al. Indications for cardiac resynchronization therapy: 2011 update from the HF Society of America Guideline Committee. J Card Fail 2012; 18:94-106.
51. Swindle JP, Rich MW, McCann P, et al. Implantable cardiac device procedures in older patients: Use and in-hospital outcomes. Arch Intern Med 2010; 170:631-637.
52. Foley PW, Chalil S, Khadjooi K, et al. Long-term effects of cardiac resynchronization therapy in octogenarians: A comparative study with a younger population. Europace 2008; 10:1302-1307.
53. Fumagalli S, Valsecchi S, Boriani G, et al. Comparison of the usefulness of cardiac resynchronization therapy in three age groups (<65, 65-74, -75 years) (from the InSync/InSync ICD Italian registry). Am J Cardiol 2011; 107:1510-1516.
54. Strimel W, Koplik S, Chen HR, et al. Safety and effectiveness of primary prevention cardioverter defibrillators in octogenarians. Pacing Clin Electrophysiol 2011; 34:900-906.
55. O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic HF: HF-ACTION randomized controlled trial. JAMA 2009; 301:1439-1450.
56. Brubaker PH, Moore JB, Stewart KP, et al. Endurance exercise training in older patients with HF: Results from a randomized controlled, single-blind trial. J Am Geriatr Soc 2009; 57:1982-1989.
57. Jó nsdó ttir S, Andersen KK, Sigurosson AF, Sigurosson SB. The effect of physical training in chronic HF. Eur J Heart Fail 2006; 8:97-101.
58. Phil E, Cider A, Stromberg A, et al. Exercise in elderly patients with chronic HF in primary care: Effects on physical capacity and health-related quality of life. Eur J Cardiovasc Nurs 2011; 10:150-158.
59. Low J, Pattenden J, Candy B, et al. Palliative care in advanced HF: An international review of the perspectives of recipients and health professionals on care provision. J Card Fail 2011; 17:231-252.
60. Goodlin SJ, Hauptman PJ, Arnold R, et al. Consensus statement; palliative and supportive care in advanced HF. J Card Fail 2004; 10:200-209.
61. Whellan DJ, Cox M, Hernandez AF, et al. Utilization of hospice and predicted mortality risk among older patients hospitalized with HF: findings from GWTG-HF. J Card Fail 2012; 18:471-477.
62. Tanner CE, Fromme EK, Goodlin SJ. Ethics in the treatment of advanced HF; palliative care and end-of-life issues. Congest Heart Fail 2011; 17:235-240.
63. McClung JA. End of life care in the treatment of advanced HF in the elderly. Cardiol Rev 2013; 21:9-15.
64. Brunner-La Rocca HP, Rickenbacher P, Muzzarelli S, et al. End-of-life preferences of elderly patients with chronic HF. Eur Heart J 2012; 33:752-759.
65. Stevenson LW, Hellkamp AS, Leier CV, et al. Changing preferences for survival after hospitalization with advanced HF. J Am Coll Cardiol 2008; 52:1702-1708.